Statin Therapy for Cardiac Hypertrophy and Heart Failure
Author:
- 1 April 2004
- journal article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 52 (4) , 248-253
Abstract
Cardiac hypertrophy leading to heart failure is a major cause of morbidity and mortality worldwide. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, have been shown to inhibit cardiac hypertrophy and improve symptoms of heart failure by cholesterol-independent mechanisms. Statins block the isoprenylation and function of members of the Rho guanosine triphosphatase family, such as Rad and RhoA. Because Rad is a requisite component of reduced nicotinamide adenine dinucleotide phosphate oxidase, which is a major source of reactive oxygen species in cardiovascular cells, the ability of statins to inhibit Rad-mediated oxidative stress contributes importantly to their inhibitory effects on cardiac hypertrophy. Furthermore, inhibition of RhoA by statins leads to the activation of protein kinase B/Akt and up-regulation of endothelial nitric oxide synthase in the endothelium and the heart. This results in increased angiogenesis and myocardial perfusion, decreased myocardial apoptosis, and improvement in endothelial and cardiac function. Because these effects of statins occur independently of cholesterol lowering, statins may have therapeutic benefits in nonhyperlipidemic patients with cardiac hypertrophy and heart failure.Keywords
This publication has 44 references indexed in Scilit:
- Preservation of NO production by statins in the treatment of heart failureCardiovascular Research, 2003
- Association of Pravastatin and Left Ventricular Mass in Hypercholesterolemic Patients: Role of 8-Iso-Prostaglandin F2α FormationJournal of Cardiovascular Pharmacology, 2002
- Heart Failure, Redox Alterations, and Endothelial DysfunctionHypertension, 2001
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJournal of Clinical Investigation, 2001
- HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen SpeciesHypertension, 2001
- Stimulation of a Vascular Smooth Muscle Cell NAD(P)H Oxidase by ThrombinJournal of Biological Chemistry, 1999
- Role of NADH/NADPH Oxidase–Derived H2O2in Angiotensin II–Induced Vascular HypertrophyHypertension, 1998
- Endothelin-1 Is Involved in Mechanical Stress-induced Cardiomyocyte HypertrophyJournal of Biological Chemistry, 1996
- Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S)The American Journal of Cardiology, 1995
- Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.Journal of Clinical Investigation, 1995